Drug intelligence / Profile preview

mepivacaine hydrochloride + articaine hydrochloride

Development stage: Unknown
Lead developer: Kodak
Modality: Small Molecules
Administration: Infiltration, Nerve Block

Overview

This combination involves two local anesthetics, **mepivacaine hydrochloride** and **articaine hydrochloride**, used for dental procedures. **Mepivacaine** is an amide local anesthetic with a rapid onset and medium duration, often used in infiltration and nerve block techniques. **Articaine** is also an amide local anesthetic known for its fast onset and long duration, commonly used in dental procedures. Both drugs work by blocking nerve impulses, thereby providing local anesthesia. The combination may enhance the effectiveness of anesthesia in certain dental procedures.

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)

Beyond the preview

Go deeper on mepivacaine hydrochloride + articaine hydrochloride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on mepivacaine hydrochloride + articaine hydrochloride.

Explore the full profile